Damora Therapeutics, Inc. (NASDAQ: GLTO) Stock Competitors & Peer Comparison
See GLTO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GLTO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GLTO | $21.58 | -3.36% | 34.5M | -1.78 | -$12.11 | N/A |
| RPRX | $56.93 | +0.30% | 24.9B | 10.71 | $5.25 | +1.63% |
| CORT | $121.19 | +1.33% | 12.8B | 338.69 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $79.78 | +2.33% | 6B | 81.19 | $0.97 | N/A |
| LQDA | $27.38 | +2.62% | 2.5B | 20.45 | $1.37 | N/A |
| PBH | $48.23 | +1.39% | 2.3B | 10.82 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $16.00 | +3.09% | 889.7M | -5.87 | -$2.52 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
GLTO vs RPRX Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, RPRX has a market cap of 24.9B. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while RPRX trades at $56.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas RPRX's P/E ratio is 10.71. In terms of profitability, GLTO's ROE is -0.83%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, GLTO is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
GLTO vs CORT Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, CORT has a market cap of 12.8B. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while CORT trades at $121.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas CORT's P/E ratio is 338.69. In terms of profitability, GLTO's ROE is -0.83%, compared to CORT's ROE of +0.08%. Regarding short-term risk, GLTO is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
GLTO vs WBA Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas WBA's P/E ratio is -1.64. In terms of profitability, GLTO's ROE is -0.83%, compared to WBA's ROE of -0.57%. Regarding short-term risk, GLTO is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check WBA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
GLTO vs KNSA Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while KNSA trades at $79.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas KNSA's P/E ratio is 81.19. In terms of profitability, GLTO's ROE is -0.83%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, GLTO is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
GLTO vs LQDA Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, LQDA has a market cap of 2.5B. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while LQDA trades at $27.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas LQDA's P/E ratio is 20.45. In terms of profitability, GLTO's ROE is -0.83%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, GLTO is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
GLTO vs PBH Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while PBH trades at $48.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas PBH's P/E ratio is 10.82. In terms of profitability, GLTO's ROE is -0.83%, compared to PBH's ROE of +0.09%. Regarding short-term risk, GLTO is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
GLTO vs HROWL Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas HROWL's P/E ratio is N/A. In terms of profitability, GLTO's ROE is -0.83%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, GLTO is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
GLTO vs HROWM Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas HROWM's P/E ratio is N/A. In terms of profitability, GLTO's ROE is -0.83%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, GLTO is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
GLTO vs LTGO Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, LTGO has a market cap of 889.7M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while LTGO trades at $16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas LTGO's P/E ratio is -5.87. In terms of profitability, GLTO's ROE is -0.83%, compared to LTGO's ROE of N/A. Regarding short-term risk, GLTO is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
GLTO vs HELP Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, HELP has a market cap of 664.5M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while HELP trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas HELP's P/E ratio is -2.57. In terms of profitability, GLTO's ROE is -0.83%, compared to HELP's ROE of -0.71%. Regarding short-term risk, GLTO is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
GLTO vs SVA Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas SVA's P/E ratio is -5.68. In terms of profitability, GLTO's ROE is -0.83%, compared to SVA's ROE of -0.01%. Regarding short-term risk, GLTO is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
GLTO vs CUVL Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, CUVL has a market cap of 281.4M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while CUVL trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas CUVL's P/E ratio is 12.04. In terms of profitability, GLTO's ROE is -0.83%, compared to CUVL's ROE of N/A. Regarding short-term risk, GLTO is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
GLTO vs CELG-RI Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, CELG-RI has a market cap of 233.9M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GLTO's ROE is -0.83%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, GLTO is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
GLTO vs HITI Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while HITI trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas HITI's P/E ratio is -9.53. In terms of profitability, GLTO's ROE is -0.83%, compared to HITI's ROE of -0.36%. Regarding short-term risk, GLTO is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check HITI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
GLTO vs ETRA Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, ETRA has a market cap of 193.9M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while ETRA trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas ETRA's P/E ratio is -3.45. In terms of profitability, GLTO's ROE is -0.83%, compared to ETRA's ROE of N/A. Regarding short-term risk, GLTO is more volatile compared to ETRA. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check ETRA's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
GLTO vs CTOR Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, CTOR has a market cap of 78.9M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while CTOR trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas CTOR's P/E ratio is -1.81. In terms of profitability, GLTO's ROE is -0.83%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, GLTO is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
GLTO vs ATLN Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas ATLN's P/E ratio is -0.68. In terms of profitability, GLTO's ROE is -0.83%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, GLTO is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check ATLN's competition here
Rite Aid Corporation (NYSE: RAD)
GLTO vs RAD Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas RAD's P/E ratio is -0.05. In terms of profitability, GLTO's ROE is -0.83%, compared to RAD's ROE of +2.76%. Regarding short-term risk, GLTO is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check RAD's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
GLTO vs NSRX Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, NSRX has a market cap of 30.9M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while NSRX trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas NSRX's P/E ratio is -4.99. In terms of profitability, GLTO's ROE is -0.83%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, GLTO is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
GLTO vs SCYX Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, SCYX has a market cap of 26.5M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while SCYX trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas SCYX's P/E ratio is -1.23. In terms of profitability, GLTO's ROE is -0.83%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, GLTO is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
GLTO vs COSM Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, COSM has a market cap of 17.1M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while COSM trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas COSM's P/E ratio is -0.43. In terms of profitability, GLTO's ROE is -0.83%, compared to COSM's ROE of -1.19%. Regarding short-term risk, GLTO is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check COSM's competition here
Cerenome, Inc. (NASDAQ: CNSY)
GLTO vs CNSY Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, CNSY has a market cap of 12.3M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while CNSY trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas CNSY's P/E ratio is -0.43. In terms of profitability, GLTO's ROE is -0.83%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, GLTO is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
GLTO vs BFRI Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, BFRI has a market cap of 11.8M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while BFRI trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas BFRI's P/E ratio is -1.67. In terms of profitability, GLTO's ROE is -0.83%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, GLTO is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
GLTO vs CJJD Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas CJJD's P/E ratio is -0.46. In terms of profitability, GLTO's ROE is -0.83%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, GLTO is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
GLTO vs SSY Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas SSY's P/E ratio is -2.86. In terms of profitability, GLTO's ROE is -0.83%, compared to SSY's ROE of -0.09%. Regarding short-term risk, GLTO is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
GLTO vs SCNX Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, SCNX has a market cap of 6.3M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while SCNX trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas SCNX's P/E ratio is -1.84. In terms of profitability, GLTO's ROE is -0.83%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, GLTO is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check SCNX's competition here
POMDOCTOR Ltd (NASDAQ: POM)
GLTO vs POM Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while POM trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas POM's P/E ratio is -0.11. In terms of profitability, GLTO's ROE is -0.83%, compared to POM's ROE of +0.16%. Regarding short-term risk, GLTO is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
GLTO vs BGMS Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, BGMS has a market cap of 4.5M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while BGMS trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas BGMS's P/E ratio is -0.23. In terms of profitability, GLTO's ROE is -0.83%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, GLTO is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check BGMS's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
GLTO vs BFRIW Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, BFRIW has a market cap of 4.3M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while BFRIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas BFRIW's P/E ratio is -0.01. In terms of profitability, GLTO's ROE is -0.83%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, GLTO is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check BFRIW's competition here
Eocene Ltd. (NASDAQ: EOCN)
GLTO vs EOCN Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, EOCN has a market cap of 3.8M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while EOCN trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas EOCN's P/E ratio is -0.26. In terms of profitability, GLTO's ROE is -0.83%, compared to EOCN's ROE of N/A. Regarding short-term risk, GLTO is more volatile compared to EOCN. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check EOCN's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
GLTO vs PAVS Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, PAVS has a market cap of 3.1M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while PAVS trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas PAVS's P/E ratio is -0.04. In terms of profitability, GLTO's ROE is -0.83%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, GLTO is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
GLTO vs MDVL Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas MDVL's P/E ratio is -0.05. In terms of profitability, GLTO's ROE is -0.83%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, GLTO is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
GLTO vs ATNFW Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas ATNFW's P/E ratio is N/A. In terms of profitability, GLTO's ROE is -0.83%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, GLTO is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
GLTO vs BGMSP Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, GLTO's ROE is -0.83%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, GLTO is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
GLTO vs AZNH Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas AZNH's P/E ratio is 38.35. In terms of profitability, GLTO's ROE is -0.83%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, GLTO is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
GLTO vs LFLYW Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, GLTO's ROE is -0.83%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, GLTO is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
GLTO vs PRPH Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, PRPH has a market cap of 140.2K. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas PRPH's P/E ratio is N/A. In terms of profitability, GLTO's ROE is -0.83%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, GLTO is more volatile compared to PRPH. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check PRPH's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
GLTO vs OREX Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, OREX has a market cap of 0. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas OREX's P/E ratio is -0.14. In terms of profitability, GLTO's ROE is -0.83%, compared to OREX's ROE of -0.54%. Regarding short-term risk, GLTO is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check OREX's competition here
Shire plc (NASDAQ: SHPG)
GLTO vs SHPG Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas SHPG's P/E ratio is 11.35. In terms of profitability, GLTO's ROE is -0.83%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, GLTO is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check SHPG's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
GLTO vs IPXL Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas IPXL's P/E ratio is -10.11. In terms of profitability, GLTO's ROE is -0.83%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, GLTO is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check IPXL's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
GLTO vs CPD Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, CPD has a market cap of 0. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas CPD's P/E ratio is N/A. In terms of profitability, GLTO's ROE is -0.83%, compared to CPD's ROE of N/A. Regarding short-term risk, GLTO is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check CPD's competition here
POZEN Inc. (NASDAQ: POZN)
GLTO vs POZN Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, POZN has a market cap of 0. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas POZN's P/E ratio is N/A. In terms of profitability, GLTO's ROE is -0.83%, compared to POZN's ROE of +0.61%. Regarding short-term risk, GLTO is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for GLTO.Check POZN's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
GLTO vs ESRX Comparison October 2026
Damora Therapeutics, Inc. (NASDAQ: GLTO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLTO stands at 34.5M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, GLTO is priced at $21.58 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLTO currently has a P/E ratio of -1.78, whereas ESRX's P/E ratio is 10.69. In terms of profitability, GLTO's ROE is -0.83%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, GLTO is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for GLTO.Check ESRX's competition here